Month: February 2016

Indication-Market Insights, Epidemiology and Market Forecast,2010-2020:DelveInsight’s New Launch

Posted on Updated on

DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products.

The database of DelveInsight currently has over 3000 reports which elaborate the domains of Indication Insight, Mechanism of Action, Drug Insights and API Insights. In addition to that, DelveInsight is providing Therapeutic intelligence to the companies with Strategic reports on Immuno-Oncology, Gene Therapy, Stem Cell Therapy, Antibody-Drug Conjugates and many more.

Market insights, epidemiology and market forecasting reports provides an insight on the forecast of a indication over a period of time which helps an organization to better understand the business development strategies from present and futuristic point of view.

DelveInsight expertise has expanded from an initial focus on Pipeline & Marketed Reports to Market Forecasting and Epidemiology Reports.  With the dedicated analytical and forecasting team, DelveInsight has released 13 Reports on Market insights, epidemiology and market forecast Reports. These Reports will provide an insight on the forecast of the indication in seven major markets during 2010-2020. The epidemiological forecast for the diagnosed prevalence of the disease in 7MM is supported by the data which has been obtained from studies conducted in the respective countries.

Therapeutic Areas Focused

  • Acute Myeloid Leukemia (AML)
  • Duchenne Muscular Dystrophy
  • Hemophilia
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Multiple Myeloma
  • Nonalcoholic Steatohepatitis (NASH)
  • Non-Hodgkin’s Lymphoma (NHL)
  • Pancreatic Cancer
  • Pulmonary Arterial Hypertension (PAH)
  • Respiratory Syncytial virus (RSV)
  • Rheumatoid Arthritis (RA)
  • Short Bowel Syndrome
  • Ulcerative Colitis (UC)

Market Forecast

The Indication- market insights, epidemiology and market forecast 2010-2020, provides clients the detailed insights into epidemiology of the indication in these countries. This report majorly includes:

  • Country specific forecast for the indication during 2010-2020.
  • The risk factors, comorbidities and global trends for the disease in the 7MM.
  • High quality, elucidating, transparent and market-driven report, providing expert analysis of disease trends in the 7MM.

This epidemiological analysis report will aid in the development of business strategies by providing a deep understanding of the trend shaping and driving the global insight market.  Along with that, it quantifies the patient populations in the global indication market to improve product design, pricing, and launch plans.

For more information on Indication – Market insights, Epidemiology and Market Forecast 2010-2020, email at info@delveInsight.com

 About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

 

 

 

“Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016” – A DelveInsight Report

Posted on

DelveInsight, the leading market research and consulting company has added a new report “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016” to its portfolio.

The Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:

Information on 215+ products and 50+ different technologies along with 70+ companies actively involved in drug development. There are 5 drugs in phase III, 22 in phase II, 42 in phase I, and 87 in pre-clinical, 28 in discovery, 16 dormant and 19 discontinued drugs.

Brentuximab Vedotin,developed by Seattle Genetics, is the leading product.

R&D activities and technologies used along with the pipeline molecules in development.

Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the in-depth analysis of Antibody Drug Conjugate Landscape across the globe. Therefore the report on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provide information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 2950 as a single user license, USD 5900 as a site license and USD 8850 as a Global/Enterprise License.

For more information on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report, email at info@delveInsight.com

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 -A DelveInsight Report

Posted on Updated on

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA). DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 has received great response and feedback from clients.
PD-1and PDL-1 is the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer.
Reports Highlights:
  • PD-1 and PD-L1 Inhibitors Therapy Pipeline scenario
  • Collaborations & partnering deals
  • Current Prominent Research Areas and Key Players
  • Pipeline product profiles PD-1 and PD-L1 Inhibitors Technologies
  • Market Drivers and Barriers
Report Coverage:
40+ products, 30+ companies and 15+ different technologies
PD-1/PDL-1 Inhibitors report provides the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors. In addition, the report provides the development of combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) along with the information on ongoing collaborations for the development of combinations regimens.
 PD-1/PDL-1 Inhibitors report report covers the therapeutics assessment of pipeline molecules by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. The reports also cover Commercial Aspects such as the Current and Future Market, market drivers and barriers followed by SWOT Analysis
The Reports will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.
DelveInsight is offering the Report at a price of USD 2,950 as a single user license, USD 5,900 as a site license andUSD 8,850 as a Global/Enterprise License.
For more information mail us at info@delveinsight.com
About Us:
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.